As I understand, the commercialisation of ArTiMist is significantly derisked given that the formulation is based on an already proven and effective compound - Artemether. So the real question remains is the delivery of this agent in liquid form at least as effective as in tablet form. Hopefully the Phase III trials yield significant results - this should really be investors main concern. The SP will then look after itself. I can't really understand why the SP is still low, given Phase III underway, given Patterson's valuation, etc. Although I guess EMS remains a bit of an unknown. Maybe this is to our advantage now? Bought more at 5.7 yesterday, just hoping for good results.
EMS Price at posting:
6.0¢ Sentiment: Buy Disclosure: Held
